MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Bringing Researchers Next-Level Tools for Hard-to-Treat Diseases

 Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is looking to give oncology drug developers an upper hand, thereby increasing the chances of the drugs’ success from the onset. “Raising the success rate for experimental cancer drugs starts in the laboratory, where leading-edge technology could be instrumental in providing prescient insights that ultimately result in better clinical outcomes,” reads a recent article. TumorGenesis, a subsidiary of POAI, has partnered with Swedish cell culture system company Cellevate AB. “The collaboration will involve using TumorGenesis’ expertise in cancer cell culture growth in combination with Cellevate’s specialty in the emerging field of nanofiber matrixes. The initial indication for the partners is ovarian cancer.” The goal is to bring researchers the next level of tools for hard-to-treat diseases, helping them avoid early mistakes that contribute to the already exorbitant cost of drug development. “The partnership provides new opportunities for both companies. It further represents an expansion of the Predictive Oncology product portfolio into an area it hadn’t addressed before.”

To view the full article, visit https://ibn.fm/a5xkZ

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical, and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins, including vaccines, antibodies, large and small proteins, and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Brain Scientific Inc.’s (BRSF) Pediatric NeuroCap Is First-of-its-Kind for Pediatric Market

 Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is bringing to market new technology that allows EEG testing to be deployed rapidly and accurately in children and adolescents. The Pediatric NeuroCap is intended to solve significant barriers limiting EEG monitoring in pediatric care. “Instead of improvising to make adult-size EEG electrodes fit pediatric patients’ smaller head circumference, Brain Scientific fully adapted its revolutionary NeuroCap to be used in children,” reads a recent article. “The Pediatric NeuroCap comes in two sizes and includes 22 integrated, pre-gelled electrodes compliant with the 10-20 international system. With the Pediatric NeuroCap, the logistical struggle to perform EEG testing in pediatric patients appears on its way to be solved — the testing can be conducted within five minutes by any member of the clinical team. The Pediatric NeuroCap is positioned to be the first disposable and pre-gelled headset available for the pediatric market, bringing faster, more efficient and sanitary brain diagnostics to the pediatric setting.”

To view the full article, visit https://ibn.fm/BBA22

About Brain Scientific Inc.

Brain Scientific is a commercial-stage healthcare company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices, or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) Announces the Postponement of FY2021 Earnings Report, Conference Call

 The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER), a producer of premium bottled alkaline water, flavor-infused waters and CBD-infused products sold under the brand names Alkaline88(R), A88 Infused(TM) and A88CBD(TM), announced that the company has not filed its 10-K full-year fiscal year 2021 earnings results. As a result, the company has postponed its earnings call. The company is recognized for its flagship product, Alkaline88, which features an innovative, state-of-the-art proprietary electrolysis process and delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes. The company also offers a line of flavor-infused beverages and a line of CBD-infused products that include salves, balms, lotions, essential oils, bath salts, powder packs, oil tinctures, capsules and gummies.

To view the full press release, visit https://ibn.fm/GYVsT

About The Alkaline Water Company

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88(R) delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked Clean Beverage label. Quickly being recognized as a growing lifestyle brand, Alkaline88(R) launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused(TM) flavored water is available in six unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp-extract salves, balms, lotions, essential oils, bath salts, powder packs, oil tinctures, capsules and gummies. To learn more about the company, please visit www.A88CBD.com and www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – FingerMotion Inc. (FNGR) Leverages Expansion Resolve, Telecom Partnerships to Build Platform

FingerMotion (OTCQX: FNGR) recently released its financial results for the fiscal year ended February 28, 2021, posting “its highest revenue and year-over-year revenue growth thus far.” According to a recent article, the company’s revenue grew by 82% from the previous financial year 2020, reaching $16.68 million. FNGR’s SMS and MMS segment posted business revenue of $6.13 million for the 2021 fiscal year, an 84% growth from the year before. Its gross profit increased by 71%. The company’s overall growth for the 2021 financial year reflected $2.11 million in positive shareholders’ equity. The article continues, “The 2021 impressive fiscal performance was mainly attributed to the company’s commitment to growth in its subscribers, a factor that, Mr. Shen [FNGR’s CEO] noted, will further allow for the increase in revenue for the coming financial year. Additionally, Mr. Shen stated that the company’s resolve to expand into new regions, coupled with fostering solid relationships with other players in the telecommunications industry, is set to guarantee its platform’s reliability and spur customer loyalty.”

To view the full article, visit https://ibn.fm/Se3xs

About FingerMotion Inc.

FingerMotion is an evolving technology company with core competencies in mobile payment and recharge platform solutions in China. It is one of only a few companies in China with access to wholesale rechargeable minutes from the country’s largest mobile phone providers that can be resold to consumers. As the user base of its primary business continues to grow, the company is developing additional value-added technologies to market to its users. FingerMotion’s vision is to rapidly grow the user base through organic means and have this growth develop into an ecosystem of users with high-engagement rates utilizing its innovative applications. Developing a highly engaged ecosystem of users would strategically position the company to onboard larger customer bases. FingerMotion eventually hopes to serve over 1 billion users in China and eventually expand the model to other regional markets. For more information about the company, visit www.FingerMotion.com.

NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Pressure BioSciences Inc.’s (PBIO) UST(TM) Platform Delivers Breakthrough Results Processing One of the Most Powerful Antioxidants Known to Science

 Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform technology solutions to the worldwide biotechnology and other industries, today announced the successful application of its Ultra Shear Technology(TM) (“UST(TM)”) platform. According to the update, the novel UST platform was used for the development of more potent formulations of wide-ranging nutraceuticals of high therapeutic value, allowing for more controlled dosing and opportunities for lower cost solutions for both manufacturers and consumers. Specifically, PBI reported breakthrough results in processing one of the most powerful antioxidants known to science, astaxanthin (“AsX”), in extremely fine and uniform, monodisperse nanoemulsions of oil in water. These results are critically important for fast and efficient absorption by the water-based biochemistry of humans and animals. “Nanoemulsions produced by PBI’s UST platform encapsulate AsX in extremely small oil droplets ranging in size from 30-60 nm in diameter*,” said Gary B. Smejkal, senior research scientist at PBI, explaining the breakthrough achieved by the company. “Because these particles are so small, they do not scatter light and thus appear as clear ruby red liquids that disperse freely in water or other clear beverages. The enhanced oral bioavailability of AsX corresponding to droplet size reduction is well-established and has been published**.”

To view the full press release, visit https://ibn.fm/2ek5M

About Pressure BioSciences Inc.

Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The company’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) recently acquired, patented technology from BaroFold Inc. (the BaroFold technology) to allow entry into the bio-pharma contract services sector, and (2) recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information about the company, visit www.PressureBioSciences.com.

*https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150732/

**https://www.academia.edu/12327321/Enhanced_Oral_Bioavailability_of_Astaxanthin_with_Droplet_Size_Reduction

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

SRAX Inc.’s (NASDAQ: SRAX) Premier Investor Real-Time Analytics Platform, Sequire, Helping 180+ Public Companies Track 5M+ Investors

 

• SRAX’s Sequire SaaS platform provides tools to help public companies track shareholders, manage warrants, issue shareholder surveys
• SRAX recently featured in Wall Street Journal article highlighting volatility problems for public companies
• Sequire subscriber base doubled between Q3 and Q4 2020 to 183 public companies across 5 million+ active traders, investors

SRAX (NASDAQ: SRAX), a financial technology company, helps publicly traded companies unlock data and insights with Sequire, its SaaS investor analytics platform that features a unique set of tools that allows users to track investors, manage warrants, publish news and issue surveys. Since its creation in 2019, the platform has bloomed to over 5 million active retail investors across 180+ companies (https://ibn.fm/6cBli), nearly doubling its year-over-year bookings to $10 million in the first quarter of 2021 (https://ibn.fm/HHR8w).  

“Retail investors are more important now than ever, as they have been driving the market, and companies are starting to pay attention,” said SRAX founder and CEO Christopher Miglino. “Data on who investors are and what they invest in is a valuable asset to every public company. This data provides us deep insights into trends and movements of all types of investors.” 

Economic and political factors underpinned the severe market volatility experienced throughout much of 2020 and early 2021. Miglino was recently featured in a Wall Street Journal article highlighting the crippling volatility issues faced by public companies and how SRAX can help them address the problem (https://ibn.fm/4psZ9). “Our sales have increased significantly over the past two quarters,” Miglino stated in the article, confirming that the platform provides critical information about shareholder activity.

As a company that went public in 2012, SRAX management intimately understands the challenges faced by public companies, and built the platform specifically to help managers unlock the power of critical market data. Features like the Situation Room produce real-time market information, including level two trading data, current share price, volume change, % change, and more. In addition, the warrant management feature manages warrant holders’ activity and keeps track of warrant expiration dates while calculating proceeds at different price scenarios in an interactive data-driven environment. 

Sequire doesn’t stop at providing insights – the platform allows users to take action through communication1 tools that engage new and existing investors through marketing campaigns across email, social media, and more. 

“Our team did an amazing job in delivering a number of cutting-edge technological improvements to the platform and they have laid the foundation for some amazing enhancements that we will bring to market throughout the rest of this year,” said Miglino. “I could not be more proud of the hard work and dedication that the team has demonstrated as our sales continue to skyrocket.”

SRAX is committed to helping public companies unlock the power of data through Sequire, its premier investor intelligence and communication SaaS platform. As concerns about market volatility continue to mount, public companies are turning to Sequire to access tools that provide clarity, increase engagement, and build loyalty with shareholders. 

For more information, visit the company’s websites at www.SRAX.com and www.MySequire.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX 

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Business Update, Progress on Driving Berubicin’s Development

 CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today provided a business update. Among the highlights, the company reported on its continued progress to drive Berubicin towards commercialization for the treatment of glioblastoma multiforme (“GBM”). “In the last 60 days alone, we have achieved fundamental clinical, regulatory and corporate milestones that together demonstrate CNS’ operational, strategic and financial strengths. We are continuously de-risking our Berubicin clinical program by driving development of this truly novel treatment forward as expeditiously as possible. In a mere 18 months from our IPO, our laser focus on this program created a potentially pivotal study now open for enrollment with patient dosing expected to commence at any time. With the addition of our recent Fast Track Designation for GBM, we believe we are poised to execute on our milestones ahead and bring a meaningful treatment to patients who suffer from this devasting and heretofore incurable disease,” said John Climaco, CEO of CNS Pharmaceuticals. “Additionally, the $4.7 million of ATM transactions significantly bolsters our cash runway and provides funding to advance our important clinical programs for several quarters to come. We are passionate about driving Berubicin’s development forward, creating value in the near- and long-term, and, most importantly, making a positive impact on patients’ lives.”

To view the full press release, visit https://ibn.fm/Q8Dip

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html